Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:CGEM NASDAQ:FULC NASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$2.24-4.3%$2.06$1.33▼$3.58$105.57M0.75135,559 shs97,683 shsCGEMCullinan Therapeutics$6.53-1.4%$7.59$6.37▼$18.62$385.75M-0.08509,022 shs753,813 shsFULCFulcrum Therapeutics$7.00+0.1%$7.08$2.32▼$8.50$378.10M2.82390,128 shs353,055 shsKMDAKamada$7.02+0.1%$7.33$5.17▼$9.15$403.40M0.8947,511 shs25,758 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-4.27%+1.82%+35.76%+14.87%-27.51%CGEMCullinan Therapeutics-1.36%-6.58%-14.53%-24.16%-63.68%FULCFulcrum Therapeutics+0.14%-8.62%+2.19%+2.19%-20.90%KMDAKamada+0.14%-1.68%-4.88%+2.03%+33.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$2.24-4.3%$2.06$1.33▼$3.58$105.57M0.75135,559 shs97,683 shsCGEMCullinan Therapeutics$6.53-1.4%$7.59$6.37▼$18.62$385.75M-0.08509,022 shs753,813 shsFULCFulcrum Therapeutics$7.00+0.1%$7.08$2.32▼$8.50$378.10M2.82390,128 shs353,055 shsKMDAKamada$7.02+0.1%$7.33$5.17▼$9.15$403.40M0.8947,511 shs25,758 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-4.27%+1.82%+35.76%+14.87%-27.51%CGEMCullinan Therapeutics-1.36%-6.58%-14.53%-24.16%-63.68%FULCFulcrum Therapeutics+0.14%-8.62%+2.19%+2.19%-20.90%KMDAKamada+0.14%-1.68%-4.88%+2.03%+33.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 3.00Buy$7.00212.50% UpsideCGEMCullinan Therapeutics 3.00Buy$27.67323.69% UpsideFULCFulcrum Therapeutics 3.00Buy$9.6037.14% UpsideKMDAKamada 2.67Moderate Buy$13.0085.19% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, FULC, CGEM, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/10/2025CGEMCullinan TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.008/21/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/18/2025CGEMCullinan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $28.008/15/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.008/6/2025ADAGAdageneLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/6/2025ADAGAdageneLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K1,055.71N/AN/A$1.14 per share1.96CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.14 per shareN/AFULCFulcrum TherapeuticsN/AN/AN/AN/A$4.51 per shareN/AKMDAKamada$160.95M2.51$0.49 per share14.27$4.51 per share1.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/AN/ACGEMCullinan Therapeutics-$167.38M-$3.23N/AN/AN/AN/A-36.56%-34.82%11/6/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)KMDAKamada$14.46M$0.3420.6521.940.7411.22%7.41%5.18%11/12/2025 (Estimated)Latest ADAG, FULC, CGEM, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KMDAKamada$0.09$0.13+$0.04$0.13$158.59 million$44.75 million8/7/2025Q2 2025CGEMCullinan Therapeutics-$0.83-$1.07-$0.24-$1.07N/AN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.292.30CGEMCullinan TherapeuticsN/A9.839.83FULCFulcrum TherapeuticsN/A24.4224.42KMDAKamadaN/A4.002.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%CGEMCullinan Therapeutics86.31%FULCFulcrum Therapeutics89.83%KMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%CGEMCullinan Therapeutics7.16%FULCFulcrum Therapeutics7.00%KMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.13 million37.14 millionNot OptionableCGEMCullinan Therapeutics3059.07 million54.84 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableADAG, FULC, CGEM, and KMDA HeadlinesRecent News About These CompaniesKamada Ltd. (NASDAQ:KMDA) Short Interest UpdateSeptember 10 at 8:19 PM | marketbeat.comKamada (NASDAQ:KMDA) Shares Pass Below 200 Day Moving Average - Here's What HappenedSeptember 6, 2025 | marketbeat.comKamada (KMDA) is an Incredible Growth Stock: 3 Reasons WhySeptember 3, 2025 | msn.comWall Street Analysts See an 110.11% Upside in Kamada (KMDA): Can the Stock Really Move This High?September 3, 2025 | zacks.comKamada to Participate in Upcoming September Investor ConferencesSeptember 2, 2025 | finance.yahoo.comKamada Ltd. Engages Investors at September ConferencesSeptember 2, 2025 | tipranks.comKMDA or ARGX: Which Is the Better Value Stock Right Now?September 1, 2025 | zacks.comKamada Ltd’s Earnings Call: Positive Growth and Strategic InitiativesAugust 31, 2025 | tipranks.comKamada: Earnings Expansion Cycle With Embedded Margin Of SafetyAugust 27, 2025 | seekingalpha.comKamada (NASDAQ:KMDA) Stock Crosses Below 200-Day Moving Average - Here's What HappenedAugust 24, 2025 | marketbeat.comKamada Ltd. (NASDAQ:KMDA) Sees Significant Decline in Short InterestAugust 20, 2025 | marketbeat.com3 Reasons Growth Investors Will Love Kamada (KMDA)August 19, 2025 | msn.comKamada (NASDAQ:KMDA) Releases Earnings Results, Beats Expectations By $0.04 EPSAugust 17, 2025 | marketbeat.comHC Wainwright Has Strong Forecast for Kamada FY2025 EarningsAugust 17, 2025 | marketbeat.comKamada Ltd. (NASDAQ:KMDA) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | insidermonkey.comWhat Makes Kamada (KMDA) a New Buy StockAugust 14, 2025 | msn.comKMDA vs. ILMN: Which Stock Is the Better Value Option?August 14, 2025 | zacks.comKamada Ltd (KMDA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Increased ...August 14, 2025 | finance.yahoo.comKamada (KMDA) Reports Q2 Earnings: What Key Metrics Have to SayAugust 14, 2025 | msn.comKamada (KMDA) Q2 Earnings Top EstimatesAugust 13, 2025 | zacks.comKamada Q2 2025 Earnings PreviewAugust 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAG, FULC, CGEM, and KMDA Company DescriptionsAdagene NASDAQ:ADAG$2.24 -0.10 (-4.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.26 +0.02 (+0.89%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Cullinan Therapeutics NASDAQ:CGEM$6.53 -0.09 (-1.36%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.52 -0.01 (-0.15%) As of 09/12/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Fulcrum Therapeutics NASDAQ:FULC$7.00 +0.01 (+0.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.00 0.00 (0.00%) As of 09/12/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Kamada NASDAQ:KMDA$7.02 +0.01 (+0.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.02 0.00 (-0.07%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
